Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
FAIL · Does not pass the screen
67.57 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 18:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price67.57 USD at the 5 Nov 2026 close
Our value readFair vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.05, read 2026-11-02
Ethical does not pass the values gate
Price67.57 USD
Fair value70.00
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-28Read Markup60.27+12.1% to today ✓Accumulation gives way to Markup first Markup read since September
2026-10-25Read Accumulation60.27+12.1% to today ✓Markdown gives way to Accumulation with volume flow in agreement
2026-10-11Read Markdown57.63+17.2% to today Distribution gives way to Markdown with results news in the headlines
2026-10-02Read Distribution57.63+17.2% to today Markup gives way to Distribution after a 7% slide in 3 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Royalty Pharma plc holds its Markup at $67.57. The statistical read favours the buyers, held for 12 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 12 days
Price at the screen
$67.57
Valuation
35.32 trailing · 11.43 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.36
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
45.62%
Below 33%
Interest-bearing debt is 45.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
85.62%
Below 33%
Interest-bearing cash and securities are 85.6% of assets, above the one-third limit.
Fail
Receivables
3.30%
Below 49%
Money owed to the company is 3.3% of assets, under the 49% limit.
Pass
Revenue purity
1.41%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Royalty Pharma's business is in a permissible area, but its interest-bearing debt is about 46% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RPRX's ethical verdict changes
Today RPRX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 3% discount to our $70.00 fair value, narrow competitive moat, 16.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 3.5% discount to the base estimate.
Where our models see it going: fair-value estimate $70.00, with a range of $70.00 to $135.12, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Royalty Deals Offer Safety Without Real Edge
Picture a landlord who owns slices of bestselling medicines rather than bricks and mortar. Royalty Pharma collects payments on thirty five approved drugs plus twenty early stage candidates, delivering 11 percent revenue growth, 34 percent profit margins and 14 percent return on equity at a forward multiple of 10.4 times.
Those figures look solid and the ethical screen clears without issue, yet the opportunity rating sits at none. Our own fair value implies 13 percent upside from the current price, but analyst targets cluster lower and the narrow moat leaves little room for outperformance once key royalties mature.
Patent cliffs and the hit rate on development stage assets remain the real variables. A low multiple on a business like this often signals capped growth rather than hidden value. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RPRX trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$66.40-1.2%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$67.18+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$67.18+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$67.18+5.2%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$63.86+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$63.86+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$63.86+6.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup · changed$60.27+0.0%Entry 10
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter.
2026-10-18Markdown$58.99+2.4%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 31% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.